Downregulation of Ubiquitin Inhibits the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma

Yi Gao, MD1, Wei Mo, MD2, Li Zhong, MD2, Huimin Jia, MD2, Yiren Xu, BA1, Ji Zhang, BA1, Xiaohui Xu, MD3, Weidong Shen, PhD1, Fangjun Wang, PhD1, Tengfei Li, MD1, Pengfei Liu, PhD1, and Shuyu Zhang, PhD2,4

Abstract

Purpose: Esophageal cancer is one of the most common malignancies worldwide. Ubiquitin-dependent degradation of regulatory proteins reportedly plays a central role in diverse cellular processes. This study investigated the expression levels of ubiquitin in esophageal squamous cell carcinoma tissues and the functions of ubiquitin in the context of esophageal squamous cell carcinoma progression.

Methods: The expression of ubiquitin in esophageal squamous cell carcinoma and normal esophageal samples was determined via immunohistochemistry. Serum ubiquitin levels were determined by enzyme-linked immunosorbent assay. The association between serum ubiquitin level and clinicopathological factors was analyzed. Real-time PCR analysis was employed to measure the mRNA levels of the ubiquitin coding genes ubiquitin B and ubiquitin C. Proliferation assays, colony formation assays, and Transwell-based assays were used to determine the influence of ubiquitin on cell growth and cell invasion. Proteomic analysis was performed to identify the proteins associated with ubiquitin.

Results: Ubiquitin expression in esophageal squamous cell carcinoma tissues was markedly higher than that in normal and tumor adjacent tissues. The levels of ubiquitin in esophageal squamous cell carcinoma serum samples were significantly higher than those in healthy controls. Serum ubiquitin levels were correlated with tumor stage and lymph node metastasis. To silence the expression of ubiquitin, we knocked down the ubiquitin coding genes ubiquitin B and ubiquitin C in TE-1 and Eca-109 cells. Silencing ubiquitin resulted in the suppression of cell growth, chemoresistance, colony formation and cell migration in esophageal squamous cell carcinoma cells. Proteomic analysis in esophageal squamous cell carcinoma cells showed that knockdown of ubiquitin coding genes deregulated the expression of 159 proteins (92 were upregulated and 67 were downregulated) involved in multiple pathways. These proteins included ferritin light chain, ferritin heavy chain, cellular retinoic acid-binding protein 2, and DNA replication factor 1.

Conclusion: Ubiquitin expression is upregulated in esophageal squamous cell carcinoma tissues and serum samples. Serum ubiquitin levels were correlated with tumor stage and lymph node metastasis. Downregulation of ubiquitin suppresses the aggressive phenotypes of esophageal squamous cell carcinoma cells by complex mechanisms; ubiquitin may represent a novel target for the treatment of esophageal squamous cell carcinoma.

1 Department of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, People’s Republic of China
2 School of Radiation Medicine and Protection and State Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, People’s Republic of China
3 Department of General Surgery, The First People’s Hospital of Taicang City, Taicang Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China
4 Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, People’s Republic of China

Corresponding Authors:
Pengfei Liu, Department of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, No.3 Yingrui Rd, Jiangyin, Jiangsu 214422, People’s Republic of China. Email: pengfeimd@163.com
Shuyu Zhang, Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, People’s Republic of China. Email: zhang.shuyu@hotmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords
esophageal squamous cell carcinoma (ESCC), ubiquitin, cell proliferation, cell migration, proteomic analysis

Abbreviations
AGC, automatic gain control; ANOVA, analysis of variance; cDNA, complementary DNA; CDT1, DNA replication factor 1; CRABP2, cellular retinoic acid-binding protein 2; CT, computed tomography; DAB, diaminobenzidine; ESCC, esophageal squamous cell carcinoma; FLT, ferritin light chain; FUb, free ubiquitin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HCC, hepatocellular carcinoma; IHC, immunohistochemistry; mRNA, messenger RNA; MS, mass spectrometry; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; MUC, multi-ubiquitin chains; OD, optical density; real-time PCR, real-time polymerase chain reaction; SEM, standard error of the mean; shRNA, short-hairpin RNA; TMT, tandem mass tag; UBB, ubiquitin B; UBC, ubiquitin C; UPS, ubiquitin/proteasome system

Received: June 15, 2019; Revised: September 30, 2020; Accepted: October 21, 2020.

Introduction
Esophageal cancer is the seventh most common cancer and the sixth most common cause of cancer-related mortality. In 2018, 572,034 new cases of esophageal cancer and 508,585 esophageal cancer-related deaths were reported; more than half of these deaths occurred in China.1 There are two main histological types of esophageal cancer: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. In China, approximately 95% of esophageal cancer cases are of the ESCC type. Despite continuous advances in the management of cancer, esophageal cancer still has an unfavorable prognosis because of its late diagnosis and rapid metastasis. During the past few years, the incidence of esophageal cancer in China has declined slightly.1,3 However, with the large population base of China, the national cancer burden continues to rise, and the underlying molecular mechanisms of ESCC remain unclear.

The stability and correct degradation of intracellular proteins is essential for maintaining normal cell functions. It is well accepted that cellular proteins are degraded by three main proteolytic pathways: the ubiquitin-proteasome proteolytic pathway, lysosome-mediated proteolysis, and the caspase hydrolysis pathway.4 Ubiquitin/proteasome system (UPS)-mediated degradation of intracellular proteins influences numerous cellular processes, including signal transduction, cell cycle progression, development, apoptosis, and metabolic regulation.5-7 Lack of proper control over the UPS may contribute to pathological conditions, including cancer.8 Proteasome inhibitors, such as bortezomib and carfilzomib, have emerged as novel and promising anticancer drugs in clinical applications.9,10 Ubiquitin is a small 76-amino acid protein (8.6 kDa) that is highly conserved among eukaryotes.11 Ubiquitin is encoded by four different genes: ubiquitin B (UBB), ubiquitin C (UBC), UBA52, and RPS27A. The UBA52 and RPS27A genes encode the fusion ribosomal proteins L40 and S27a, respectively, and are thought to be essential for protein synthesis. The polyubiquitin precursor proteins are encoded by the UBB and UBC genes.12

By governing proteolysis, ubiquitin indirectly plays crucial roles in a variety of cellular processes and housekeeping functions. Altered ubiquitin levels may have a positive relationship with several cancer types. Choongseob Oh et al. found that the downregulation of ubiquitin inhibited the proliferation of breast cancer and prostate cancer cells and that ubiquitin may serve as an anticancer target.13 Studies have shown that the expression level of ubiquitin is significantly higher in hepatocellular carcinoma (HCC) than in other chronic liver diseases, which may be due to the lack of poorly differentiated HCC.14 We have previously reported that ubiquitin expression was significantly upregulated in human lung cancer cells and that silencing ubiquitin genes inhibited the proliferation and radioresistance of H1299 xenografts by promoting apoptosis.15 These findings suggest that ubiquitin may act as an inhibitor of cell growth in certain types of cancer cells.

However, the expression of ubiquitin and its function in the progression of ESCC have not been fully elucidated. In this study, we investigated the expression of ubiquitin in ESCC and normal tissue and serum samples. We further demonstrated the role of ubiquitin in driving cell proliferation and in shaping the proteomic landscape in ESCC cells.

Materials and Methods
Tissue Samples
The ESCC samples were collected from patients (n = 120) who had not received either chemotherapy or radiotherapy prior to surgery. For these patients, if preoperative ultrasonography or computed tomography (CT) did not show any enlarged cervical lymph nodes (minor axis < 0.5 cm), patients underwent a subtotal esophagectomy with two-field lymphadenectomy through a right thoracotomy, followed by a laparotomy. If enlarged cervical lymph nodes were found by preoperative ultrasonography or CT, patients underwent radical esophagectomy with cervico-thoraco-abdominal three-field lymphadenectomy through a right thoracotomy, followed by a laparotomy and cervical incision. The resection included nodes along the cervical part of the esophagus and deep cervix. Tumor adjacent tissues were collected 3 cm away from the tumor. Fifteen normal esophageal tissue samples were obtained from upper...
endoscopies of trauma patients, which were performed by the same operator. These tissues were obtained postoperatively between 2010 and 2012 from the Gastrointestinal Center, Jiangyin People’s Hospital, the Jiangyin Clinical College of Xuzhou Medical University, (Jiangyin, China) as reported previously.16 All patients provided signed and informed consent for their tissue samples to be used for scientific research. Ethical approval for the study was obtained from the Jiangyin People’s Hospital, the Jiangyin Clinical College of Xuzhou Medical University. All diagnoses were based on pathological and/or cytological evidence. The histological features of the specimens were evaluated by a senior pathologist according to the classification criteria from the World Health Organization.17 Tissue samples were obtained prior to chemotherapy and radiation therapy and were immediately fixed in 10% neutral buffered formalin prior to immunohistochemistry analysis.

**Immunohistochemistry Staining (IHC)**

The tissue samples were fixed in 10% neutral buffered formalin and embedded in paraffin. Three-micrometer thick paraffin sections were deparaffinized and heat-treated with citrate buffer (pH 6.0) for 7 min as an epitope retrieval protocol. Endogenous peroxidase was blocked with 3% hydrogen peroxide for 15 min at room temperature and tissue non-specific-binding sites were blocked with 4% skim milk for 30 min. Sections were then incubated with the ubiquitin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h and 2% skim milk to reduce the non-specific staining before being incubated with the biotinylated secondary antibody for 30 min. IHC staining was visualized with a substrate solution containing diaminobenzidine (DAB) and hydrogen peroxide. Hematoxylin was used for counter-staining. All steps were performed at room temperature. The negative controls consisted of tissue sections treated with similar staining procedures in the absence of the primary antibody. The criteria for scoring the stained sections were as follows: negative, 0 < 10% of the whole tissue section stained positive; weakly positive (+ 1), 10-25% of the whole tissue section stained positive; moderately positive (+ 2), 25-75% of the whole tissue section stained positive; and strongly positive (+ 3), 75% of the tissue section stained positive. Tissues with score 0 or 1 were considered ubiquitin negative, while those with score 2 or 3 were considered as ubiquitin positive.

**Ubiquitin Detection by Enzyme-Linked Immunosorbent Assay (ELISA)**

The ESCC serum samples (n = 99) were collected from the Gastrointestinal Center, Jiangyin People’s Hospital, the Jiangyin Clinical College of Xuzhou Medical University, (Jiangyin, China) prior to any treatment. The control group (n = 49) consisted of age- and sex-matched normal healthy donors with no history of major disease, and their specimens were collected from the Health Examination Center, Jiangyin People’s Hospital, Jiangyin Clinical College of Xuzhou Medical University (Jiangyin, China). All patients provided signed and informed consent for their serum samples to be used for scientific research. Ethical approval for the study was obtained from the Jiangyin People’s Hospital, the Jiangyin Clinical College of Xuzhou Medical University. Serum samples were collected between 2018 and 2019. These samples were collected and stored in aliquots at -80°C until use. Ubiquitin in the serum of ESCC patients and healthy controls was measured using a commercial human Ubiquitin ELISA kit (Elabscience, Wuhan, China). The ubiquitin concentration in the serum was calculated using a standard curve obtained from measuring the absorbance of known concentrations of highly purified recombinant human ubiquitin and expressed in ng/mL. Briefly, 0.5 mL of serum was centrifuged at 12,000 g for 10 min at 4°C, and the supernatant was stored at -70°C for 72 h. Thawed supernatant (100 µL) was used in the ELISA according to the manufacturer’s instructions. The optical absorbance of the samples was measured at 450 nm. A serial dilution of human recombinant ubiquitin was included in each assay to obtain a standard curve from which the sample concentration of ubiquitin could be calculated in ng/mL using the measured absorbance values.

**Cell Culture and Transfection**

The human esophageal cancer cell lines TE-1 and Eca-109 were maintained in DMEM supplemented with 10% FBS and antibiotics (Gibco, Grand Island, NY). Cells were grown at 37°C with 5% CO₂.

The shRNAs targeting UBB and UBC (shRNA-UBB, shRNA-UBC) and the shRNA control (shRNA-NC) used in this study were used as reported previously.15 Cells were grown in a 6-well culture plate to 70-80% confluence and then transfected with either shRNA-NC, shRNA-UBB, or/and shRNA-UBC using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.

**Tissue Collection and RNA Extraction**

TRIzol reagent was used to extract the total RNA from the ESCC cells according to the manufacturer’s protocols. Total RNA was then eluted using 100 µL of nuclease-free water. Total RNA was quantified using a NanoDrop ND-2000 spectrophotometer (Thermo Scientific, Wilmington, MA), and RNA integrity was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA).

**Real-Time PCR Analysis**

Total RNA from ESCC cells was reverse transcribed to cDNA using an oligo(dT)₁₂ primer and Superscript II reverse transcriptase (Invitrogen). SYBR green dye (Takara, Japan) was used for amplification of cDNA. mRNA levels of the targeted genes as well as those of the internal standard, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), were measured by real-time quantitative PCR in triplicate using a Prism 7900 real-time PCR instrument (Applied Biosystems, Foster City, CA). The
primers used for the real-time PCR analysis were used as reported previously.\textsuperscript{15}

**Cell Viability Assay**

Cell viability was evaluated by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Cells were plated in 96-well plates. The next day, cells were treated with or without 100 nM cisplatin, according to the experimental design. The cells were then incubated with 20 \( \mu \)L MTT (5 mg/mL) for 4 h. The medium was removed, 100 \( \mu \)L of DMSO was added, and the optical density (OD) at 490 nm was measured using a Microplate Reader (Bio-Rad, Hercules, CA). The viability index was calculated as the experimental OD/control OD. Three independent experiments were performed in quadruplicate.

**Focus Formation**

ESCC cells transfected with the indicated vectors were plated at low density (1,000 cells per 6-cm plate), incubated for 10 days, fixed, and stained with crystal violet. Foci and colonies containing more than 50 cells were counted using a microscope.

**In Vitro Migration Assay**

Migration was assayed using a modified Boyden chamber (Corning-Costar, Cambridge, MA) that contained a polycarbonate Transwell membrane filter (6.5 mm diameter, 8 \( \mu \)m pore size). The upper chamber was plated with 1 \( \times \) 10\(^5\) TE-1 or Eca-109 cells in serum-free DMEM. The lower chamber contained 600 \( \mu \)L medium from vector- or shRNA-transfected cells. After 5 h incubation at 37\( ^\circ \)C in 5% CO\(_2\), the filter was removed. Cells on the upper surface of the filter were wiped off, while the migrated cells on the bottom surface were fixed with methanol, stained with Giemsa, and counted under a microscope.

**Protein Extraction for Proteomic Analysis**

shRNA-NC and shRNA-UBB/UBC Eca-109 cells were collected. Equal quantities of cells from three wells were mixed to generate one sample for each group. The samples were first sonicated on ice using a high intensity ultrasonic processor (Scientz, Ningbo, China) in lysis buffer (8 M urea, 1% Triton-100, 10 mM DTT (DL-Dithiothreitol), 2 mM EDTA, and 0.1% protease inhibitor cocktail). The remaining debris was removed by centrifugation at 20,000 \( \times \) g at 4\( ^\circ \)C for 10 min. Finally, the proteins were precipitated with cold 15% TCA for 2 h. at -20\( ^\circ \)C. After centrifugation at 4\( ^\circ \)C for 10 min, the supernatant was discarded and the remaining precipitate was washed three times with cold acetone. The proteins were resuspended in buffer (8 M urea and 100 mM triethylammonium bicarbonate (TEAB) at pH 8.0), and the protein concentration was determined using the 2-D Quant kit, according to the manufacturer’s instructions.

**Tryptic Digest**

The protein solution was reduced with 10 mM DTT for 1 h at 37\( ^\circ \)C and alkylated with 20 mM IAA for 45 min at room temperature. The protein sample was diluted with 100 mM TEAB to a final urea concentration of less than 2 M. Finally, trypsin was added at a 1:50 trypsin-to-protein ratio for the first overnight digestion and a 1:100 trypsin-to-protein ratio for the second 4-h digestion. Approximately 100 \( \mu \)g of protein from each sample was digested with trypsin for subsequent analysis.

**Tandem Mass Tag (TMT) Labeling**

After digestion, the tryptic peptides were desalted using a Strata X C18 SPE column (Phenomenex, Torrance, CA, USA) and vacuum-dried. Peptides were reconstituted in 0.5 M TEAB and processed with a 6-plex TMT kit according to the manufacturer’s protocol. One unit of each TMT reagent (defined as the amount of reagent required to label 100 \( \mu \)g of protein) was thawed and reconstituted in 24 \( \mu \)L acetonitrile (ACN) and added to each sample. Next, the peptide mixtures were incubated for 2 h at room temperature. The mixtures were pooled, desalted, and dried by vacuum centrifugation.

**HPLC Fractionation**

The labeled peptide sample was then fractionated by high pH reverse-phase HPLC using an Agilent Extend C18 column (5 \( \mu \)m particles, 4.6 mm ID, and 250 mm length). Peptides were separated with a gradient of 2% to 60% acetonitrile in 10 mM ammonium bicarbonate (pH 10) for over 80 min, into 80 fractions. These were then combined into 18 fractions and dried by vacuum centrifugation.

**Quantitative Proteomic Analysis by LC-MS/MS**

Peptides were dissolved in 0.1% FA and directly loaded onto a reverse-phase pre-column (Acclaim PepMap 100, Thermo Scientific, Rockford, IL, USA). Next, these peptides were separated using a reverse-phase analytical column (Thermo Scientific, Rockford, IL, USA). The gradient began with an increase from 8% to 22% in solvent B (0.1% FA in 98% ACN) over 26 min, followed by an increase from 22% to 35% over 6 min, finally rising to 80% over 4 min, and holding at 80% for the last 4 min, all at a constant flow rate of 300 nL/min on an EASY-nLC 1000 UPLC system. Spectra were obtained using a Q Exactive\textsuperscript{TM} plus hybrid quadrupole-Orbitrap mass spectrometer (Thermo, Woburn, MA, USA).

The peptides were subjected to NSI (Nano Spray Ionization) source ionization followed by tandem mass spectrometry (MS/MS) in a Q Exactive\textsuperscript{TM} plus that was coupled online to the UPLC. Intact peptides were detected at a resolution of 70,000. Peptides were fragmented for MS/MS using an NCE (Nano Capillary Electrospray) of 33, and the resulting ion fragments were detected at a resolution of 17,500. A top-20 data-dependent method was applied to the top 20 precursor ions.
above a threshold ion count of 2E4 in the MS survey scan, with a 30.0 s. dynamic exclusion. The electrospray voltage applied was 2.0 kV. The automatic gain control (AGC) setting of 5E4 ions was used to prevent overfilling of the ion trap. For MS scans, the m/z scan range was 350 to 1800. A fixed first mass was set at 100 m/z.

Database Search

The resulting spectra were processed using the Mascot search engine (v.2.3.0). Tandem mass spectra were searched against the Swiss Prot Homo sapiens database (20,274 sequences). Trypsin/P was specified as the cleavage enzyme, and up to two missing cleavages were allowed. The mass error was set to 10 ppm for the precursor ions and 0.02 Da for fragment ions. Carbamidomethyl on Cys, TMT-6plex (N-term), and TMT-6plex (K) were specified as fixed modifications, and oxidation on Met was specified as a variable modification. The FDR was <1%, and the peptide ion score was set at > 20.

We first checked the mass error of all the identified peptides. The distribution of mass error was near zero, and usually less than 0.02 Da. Most of the identified peptides were between 8 and 16 amino acids in length, which agrees with the expected length of tryptic peptides and indicates that tryptic digestion was efficient.

KEGG Annotation

KEGG analysis was performed to determine the biological roles of the differentially expressed mRNAs based on the latest

Figure 1. Overexpression of ubiquitin in ESCC tissues and serum samples. (A) Representative images of immunohistochemical (IHC) staining for ubiquitin in normal esophageal tissues, tissues adjacent to esophageal squamous-cell carcinoma (ESCC), and ESCC tissues (magnification, 200×). (B) IHC staining score for ubiquitin in normal esophageal tissues (n = 15), ESCC tissues (n = 120), and tissues adjacent to the ESCC (n = 52), * P < 0.05. (C) Scatter diagram representing the serum levels of ubiquitin in healthy controls (n = 49) and ESCC patients (n = 99). **P < 0.05.
KEGG (Kyoto Encyclopedia of Genes and Genomes) database (http://www.genome.jp/kegg/). The \( P \) value (cut-off = 0.05) denotes the significance of the pathway correlation to the tested conditions.

**Statistical Data Analysis**

Data are expressed as the mean ± standard error of the mean (SEM) of at least three independent experiments. Standard error bars are included for all data points. The data were first analyzed with the Kolmogorov-Smirnov test for data distribution normality. The data were then analyzed using Student’s \( t \)-test when only two groups were present or assessed by one-way analysis of variance (ANOVA) when more than two groups were compared. The \( P \) values for \( t \)-tests are 2-tailed \( t \)-tests. Statistical analysis was performed using SPSS software (Release 19.0, SPSS Inc.). Data were considered significant if \( P < 0.05 \).

**Results**

**Ubiquitin Expression Is Upregulated in ESCC Tissues**

To investigate the role of ubiquitin in ESCC, we first evaluated the expression of ubiquitin in ESCC tissue samples, tumor adjacent tissues and normal esophageal tissues by IHC analysis. Fifteen paraffin-embedded normal esophageal tissue samples and 120 ESCC tissues, 52 of which had corresponding adjacent tissues, were collected. Ubiquitin staining was significantly stronger in ESCC samples than in tumor adjacent or normal tissue samples. As shown in Figure 1A and B, ubiquitin expression was noticeably more pronounced in the nucleus and cytoplasm of ESCC cells. These results indicated that ubiquitin was overexpressed in ESCC and might play important roles in the progression of ESCC.

**Serum Ubiquitin Levels Are Elevated in ESCC Patients**

We next examined the serum levels of ubiquitin in 99 ESCC patients and 49 healthy controls by ELISA, and the demographic features of the patients are summarized in Table 1. The results revealed that the serum levels of ubiquitin in the ESCC group were notably higher than those in the control group. The mean serum levels of ubiquitin were 78.869 ± 7.418 ng/ml in the ESCC group, and 42.946 ± 4.098 ng/ml in the control group (\( P = 0.0013 \); Figure 1C). These results indicated elevated levels of circulating ubiquitin in ESCC patients, suggesting that ubiquitin may be correlated with ESCC progression.

**Association of Serum Ubiquitin Level With Clinicopathological Factors**

The relationship between serum ubiquitin level and clinicopathological factors is shown in Table 2. The serum ubiquitin level was correlated with an advanced tumor stage (\( P = 0.026 \)). The serum ubiquitin level was found to be significantly higher in stage III-IV than in stage I-II tumors (94.219 ± 11.888 vs. 61.18 ± 27.536, \( P < 0.05 \)). The serum ubiquitin level was also correlated with lymph node metastasis (\( P = 0.018 \)). Other clinicopathological parameters, including age, gender and tumor location, showed a non-significant correlation with serum ubiquitin levels. These results suggest that ubiquitin is a characteristic of ESCC.

**Knockdown of Ubiquitin Attenuated the Aggressive Phenotypes in ESCC Cells**

To determine whether ubiquitin is associated with aggressive phenotypes in ESCC cells, we knocked-down ubiquitin in Eca-

---

**Table 1. Patient Demographic Features for the Serum Ubiquitin Analysis.**

|                  | Normal | Grade I | Grade II | Grade III | Grade IV | All tumors |
|------------------|--------|---------|----------|-----------|----------|------------|
| Number           | 49     | 18      | 28       | 31        | 22       | 99         |
| Mean age (years) | 65.35  | 65.67   | 67.71    | 64.87     | 67.77    | 66.46      |
| Age range (years)| 56-79  | 53-78   | 52-91    | 48-79     | 51-80    | 48-91      |
| Gender           |        |         |          |           |          |            |
| Male             | 37     | 13      | 21       | 25        | 18       | 77         |
| Female           | 12     | 5       | 7        | 6         | 4        | 22         |

**Table 2. Relationship Between Clinicopathological Features and Serum Ubiquitin Levels.**

| Clinicopathological parameters | Serum ubiquitin level (ng/ml) | \( P \)-Value |
|-------------------------------|-------------------------------|--------------|
| Age (years)                   |                               |              |
| <64                           | 36                            | 83.205 ± 16.960 | 0.710   |
| ≥64                           | 63                            | 76.391 ± 6.605 | 0.368   |
| Gender                        |                               |              |
| Male                          | 77                            | 82.460 ± 9.030 | 0.417   |
| Female                        | 22                            | 66.300 ± 10.636 | 0.202   |
| Tumor location                |                               |              |
| upper                         | 19                            | 85.561 ± 26.641 | 0.171   |
| middle                        | 50                            | 85.307 ± 9.697 | 0.171   |
| lower                         | 30                            | 63.901 ± 7.665 | 0.171   |
| Stage                         |                               |              |
| I-II                          | 46                            | 61.182 ± 7.536 | 0.026   |
| III-IV                        | 53                            | 94.219 ± 11.888 | 0.018   |
| pN (+)                        | 59                            | 93.181 ± 11.031 | 0.018   |
| pN (-)                        | 40                            | 57.758 ± 7.494  | 0.018   |

Abbreviations: pN, lymph node metastasis.
109 and TE-1 cell lines. The cells were transfected either with the shRNA control (shNC) or with 4 shRNAs targeting UBB or UBC (Figure 2A). As measured by real-time PCR analysis, the most effective shRNAs for the knockdown of UBB and UBC were shRNA-1 and shRNA-2, respectively, in both Eca-109 and TE-1 cells (Figures 2B and C). Therefore, a mixture of shRNA-1 for UBB and shRNA-2 for UBC was used in the following experiments.

We first evaluated the effect of the knockdown of ubiquitin coding genes on the viability of ESCC cells. As shown in the MTT assay (Figure 3A and B), knockdown of UBB/UBC appeared to suppress the cell viability of Eca-109 and TE-1 cells with or without cisplatin. The effect of ubiquitin silencing on the growth of ESCC cells was determined by colony formation assay. The results demonstrated that decreased ubiquitin expression significantly suppressed cell proliferation (Figure 3C). The combined knockdown of UBB and UBC also significantly decreased the migration and invasion of Eca-109 and TE-1 cells (Figure 3D). These results indicated that silencing of ubiquitin coding genes (UBB and UBC) abrogated the aggressive phenotypes of ESCC cells.

**Proteomic Analysis of Dysregulated Proteins in Ubiquitin Silenced ESCC Cells**

Since ubiquitin is involved in protein ubiquitination and subsequent protein degradation, we therefore explored the differences in protein dysregulation between parental and ubiquitin-silenced ESCC cells by proteomic analysis. In total, 4,774 proteins were quantified from the two groups of esophageal cancer cells. When the t-test $P$ value was set at 0.05 and both the upregulation and downregulation threshold
quantification ratios were set at 1.2, 159 dysregulated proteins were found (92 upregulated and 67 downregulated; Figures 4A and B and Table 3). The differentially expressed proteins included ferritin light chain, ferritin heavy chain, CRABP2, and CDT1 (Figure 4C). KEGG pathway analysis is widely used in molecular interaction networks and can provide higher order functional meaning and genomic information on cells and organisms. As expected, proteins from multiple pathways were dysregulated. The significantly affected pathways included influenza A response, protein digestion and absorption, and folate biosynthesis (Figure 4D).

Discussion
Ubiquitin-dependent degradation of regulatory proteins is involved in key cellular processes, including cell cycle progression, cell proliferation, apoptosis, and DNA damage response. Dysfunction of ubiquitin has been implicated in a vast array of human diseases, including cancer. Ishibashi Y et al reported that the levels of free ubiquitin (FUb) and multi-ubiquitin chains (MUC) were significantly higher in colorectal cancer tissues than in normal tissues. The level of FUb in cancerous tissues was also correlated with the depth of
invasion, while the level of MUC demonstrated a positive relationship with blood or lymphatic vessel invasion. Studies have shown that the labeling index of ubiquitination is significantly higher in human hepatocellular carcinoma than in other chronic liver diseases and tend to increase in proportion with the extent of undifferentiation.20 This study, for the first time to our knowledge, illustrates the upregulation of ubiquitin in ESCC tissue and serum samples. In this study, using IHC, we detected ubiquitin in both the nucleus and cytoplasm of ESCC cells. The protein level of ubiquitin in ESCC tissues was significantly higher than that in normal and tumor adjacent tissues. Furthermore, the serum levels of ubiquitin were markedly elevated in ESCC samples compared with healthy controls. We found that serum ubiquitin levels were correlated with tumor stage and lymph node metastasis. We therefore suggest that ubiquitin may be involved in esophageal oncogenesis and tumor development.

Cancer cells acquire their malignant capabilities through uncontrolled cell proliferation and genomic instability. The downregulation of ubiquitin inhibits numerous ubiquitination-mediated pathways and is an effective way to inhibit cell proliferation in multiple cancers, including neuroblastoma, gynecological cancer, liver hepatocellular carcinoma and lung cancer.15,20-22 Silencing ubiquitin induces apoptotic cell death, indicating that ubiquitin might be a potential target for cancer treatment.21,22 Consistent with previous studies, we found that knock-down of UBB/UBC resulted in decreased ESCC cell growth, colony formation and migration, suggesting that

**Figure 4.** Silencing of ubiquitin coding genes affected the protein profiles. (A) Volcano diagram and bar diagram showing significant differentially expressed proteins in the control and UBB/UBC silenced Eca-109 cells. (B) Heatmap of dysregulated proteins between the two groups. Expression levels are indicated by a color change. Red indicates upregulation, while green indicates downregulation. (C) Heatmap of the top 20 dysregulated proteins. (D) KEGG analysis of dysregulated proteins between the control and UBB/UBC silenced Eca-109 cells.
ubiquitin may be a potent inhibitor in esophageal cancer progression. Chemotherapy plays a crucial role in the treatment of esophageal cancer, and acquired chemoresistance is one of the main reasons for local recurrence or treatment failure. In this study, we revealed that silencing \textit{UBB/UBC} contributed to decreased chemoresistance. These results indicated that ubiquitin might be a novel target for enhancing the chemosensitivity of esophageal cancer.

To detect novel biomarkers and molecular targets in ESCC tissues, we identified 159 differentially expressed proteins (92 upregulated and 67 downregulated) between ESCC and normal esophageal tissues with an iTRAQ-based proteomic approach. The results revealed that multiple proteins were significantly upregulated, including ferritin light chain, ferritin heavy chain, CRABP2 and CDT1. Ferritin is a major driving force in iron delivery, cell proliferation and angiogenesis.\textsuperscript{23} It is overexpressed in a variety of cancer cells, including breast cancer, glioblastoma, liver cancer, lung cancer, osteosarcoma, and head and neck squamous cell carcinoma and is correlated with poor prognosis.\textsuperscript{24-30} Wu T et al reported that expression of ferritin light chain (FLT) was elevated in glioblastoma, and downregulation of FLT inhibited the proliferation of glioblastoma cells via the GADD45/JNK pathway.\textsuperscript{28} DNA replication factor 1 (CDT1) is overexpressed in hepatocellular carcinoma and breast cancer and contributes to oncogenesis.\textsuperscript{31,32} Among the upregulated proteins, cellular retinoic acid-binding protein

### Table 3. Differentially Expressed Proteins in Ubiquitin Knockdown ESCC Cells (Top 20).

| No. | Gene name | Fold-change | P-value | Description |
|-----|-----------|-------------|---------|-------------|
|     |           | Upregulation |         |             |
| 1   | FTL       | 1.91        | 2.76E-03| Ferritin light chain |
| 2   | CRABP2    | 1.71        | 4.09E-06| Cellular retinoic acid-binding protein 2 |
| 3   | FTH1      | 1.69        | 2.21E-04| Ferritin heavy chain |
| 4   | F11R      | 1.55        | 2.60E-03| Junctional adhesion molecule A |
| 5   | CDT1      | 1.47        | 3.16E-04| DNA replication factor Cdt1 |
| 6   | GLUL      | 1.46        | 4.14E-05| Glutamine synthetase |
| 7   | ALPI      | 1.45        | 9.90E-05| Intestinal-type alkaline phosphatase |
| 8   | CPM       | 1.44        | 3.00E-04| Carboxypeptidase M |
| 9   | CPVL      | 1.43        | 4.56E-03| Probable serine carboxypeptidase CPVL |
| 10  | CAV1      | 1.43        | 1.83E-04| Caveolin-1 |
| 11  | GANAB     | 1.42        | 3.31E-06| Neutral alpha-glucosidase AB |
| 12  | HIF0      | 1.41        | 1.34E-06| Histone H1.0 |
| 13  | NUCKS1    | 1.41        | 1.46E-06| Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 |
| 14  | MTMR12    | 1.4         | 1.66E-02| Myotubularin-related protein 12 |
| 15  | TBL1XR1   | 1.39        | 4.58E-04| F-box-like/WD repeat-containing protein TBL1XR1 |
| 16  | PTGS1     | 1.38        | 1.57E-04| Prostaglandin G/H synthase 1 |
| 17  | ARL2BP    | 1.38        | 4.59E-04| ADP-ribosylation factor-like protein 2-binding protein |
| 18  | NAA15     | 1.38        | 3.27E-06| "N-alpha-acetyltransferase 15, NatA auxiliary subunit |
| 19  | SAMD11    | 1.37        | 5.91E-05| Sterile alpha motif domain-containing protein 11 |
| 20  | NAA10     | 1.36        | 1.57E-04| N-alpha-acetyltransferase 10 |

|     |           | Downregulation |         |             |
|-----|-----------|----------------|---------|-------------|
| 1   | ULK3      | 0.21           | 4.35E-07| Serine/threonine-protein kinase ULK3 |
| 2   | FASTKD5   | 0.45           | 3.87E-06| FAST kinase domain-containing protein 5, mitochondrial |
| 3   | HIST1H1E  | 0.64           | 1.74E-02| Histone H1.4 |
| 4   | AKR1B1    | 0.64           | 9.35E-08| Aldose reductase |
| 5   | EPHA2     | 0.65           | 5.02E-04| Ephrin type-A receptor 2 |
| 6   | CASB      | 0.67           | 6.18E-05| "Carbonic anhydrase 5B, mitochondrial |
| 7   | HIST1H1C  | 0.69           | 9.18E-04| Histone H1.2 |
| 8   | MSMO1     | 0.69           | 2.26E-03| Methylsterol monoxygenase 1 |
| 9   | IREB2     | 0.69           | 1.38E-03| Iron-responsive element-binding protein 2 |
| 10  | HMGCS1    | 0.69           | 9.87E-05| Hydroxymethylglutaryl-CoA synthase |
| 11  | MAP2K4    | 0.69           | 3.69E-06| Dual specificity mitogen-activated protein kinase kinase 4 |
| 12  | APLP2     | 0.72           | 1.76E-03| Amyloid-like protein 2 |
| 13  | SUMF1     | 0.72           | 8.12E-03| Formylglycine-generating enzyme |
| 14  | IL18      | 0.73           | 3.83E-04| Interleukin-18 |
| 15  | UBE2C     | 0.73           | 1.60E-04| Ubiquitin-conjugating enzyme E2 C |
| 16  | GPRC5A    | 0.73           | 1.40E-03| Retinoic acid-induced protein 3 |
| 17  | ITGA2     | 0.74           | 4.66E-03| Integrin alpha-2 |
| 18  | ATP1B1    | 0.74           | 4.55E-04| Sodium/potassium-transporting ATPase subunit beta-1 |
| 19  | MMGT1     | 0.75           | 1.92E-02| Membrane magnesium transporter 1 |
| 20  | FAM45A    | 0.75           | 2.69E-02| Protein FAM45A |
2 (CRABP2) is reported to be associated with tissue differentiation and proliferation and modulate both oncogenic and anti-cancer functions. Yang Q et al. demonstrated that the protein and mRNA levels of CRABP2 were markedly lower in ESCC specimens and correlated with TNM stage, tumor size, pathology, cell differentiation, infiltration depth and occurrence position. Upregulation of CRABP2 strikingly suppressed cell proliferation, induced cell apoptosis and blocked cell metastasis; thus, it may serve as a tumor suppressor. We hypothesized that ubiquitin may mediate the biological behavior of esophageal cancer through CRABP2. Choongseob Oh et al reported that the downregulation of ubiquitin inhibited the cell proliferation and induced apoptotic cell death in cancer cells. In previous studies, we found that silencing ubiquitin genes inhibited the expression of anti-apoptotic protein Bcl-2 in lung cancer H1299 cells, and silencing ubiquitin genes suppressed the proliferation and radiosensitivity of H1299 transplanted xenografts by promoting apoptosis. Further studies are needed to explore the role of these proteins in ESCC tissues. Tumor growth and invasion involve numerous genes and pathways. Our study mainly focuses on the biological function of ubiquitin. And we’ll further explore the pathways affected by ubiquitin in subsequent studies.

In summary, our study demonstrates that ubiquitin expression is upregulated in ESCC tissues and serum samples. Serum ubiquitin levels were correlated with tumor stage and lymph node metastasis. The downregulation of UBB/UBC suppresses the proliferation, chemoresistance, and migration of esophageal cancer cells, suggesting that ubiquitin could be a promising therapeutic target for esophageal cancer. In addition, we report on proteomic changes in ESCC tissues, which provides an overview of potential biomarkers and targets for this disease.

Authors’ Note
These authors contributed equally to this work.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical Statement
This study was approved by the Ethics Committee of the Jiangyin People’s Hospital, the Jiangyin Clinical College of Xuzhou Medical University, China (approval number: 2018002). All patients provided written informed consent prior to enrollment in the study.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Natural Science Foundation of China (31670857, 81703022 and 31700737), the Natural Science Foundation of Jiangsu Province (BK20161152 and BK20171157), Jiangsu Province Key Youth Talents Project (QNRC2016262, QNRC2016136 and QNRC2016137), and the Scientific Research Program of Wuxi Municipal Health Commission (Z201808, CXTD004, QNRC092 and QNRC082).

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Zeng HM, Chen WQ, Zheng RS, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5): e555-e567.
3. Zuo TT, Zheng RS, Zeng HM, Zhang SW, Chen WQ, He J. Incidence and trend analysis of esophageal cancer in China. Zhonghua Zhong Liu Za Zhi. 2016;38(9):703-708. [Article in Chinese]
4. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008;8(11):835-850.
5. Gilberto S, Peter M. Dynamic ubiquitin signaling in cell cycle regulation. J Cell Biol. 2017;216(8):2259-2271.
6. You R, Rape M. The increasing complexity of the ubiquitin code. Nat Cell Biol. 2016;18(6):579-586.
7. Deshaies R, Joazeiro C. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78(1):399-434.
8. Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20(11):1242-1253.
9. Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013;121(6):893-897.
10. Ludwig H, Moreau P, Dimopoulos MA, et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019;9(3):23.
11. Ozkaynak E, Finley D, Solomon MJ, Varshavsky A. The yeast ubiquitin genes: a family of natural gene fusions. EMBO J. 1987;6(5):1429-1439.
12. Kimura Y, Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J Biochem. 2010;147(6):793-798.
13. Oh C, Park S, Lee EK, Yoo YJ. Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention. Sci Rep. 2013;3(9):2623.
14. Shirahashi H, Sakaida I, Terai S, Hironaka K, Kusano N, Okita K. Ubiquitin is a possible new predictive marker for the recurrence of human hepatocellular carcinoma. Liver. 2002;22(5):413-418.
15. Tang Y, Geng Y, Luo J, et al. Downregulation of ubiquitin inhibits the proliferation and radiosensitivity of non-small cell lung cancer cells in vitro and in vivo. Sci Rep. 2015;5:9476.
16. Luo J, Zhou X, Ge X, et al. Upregulation of Ying Yang 1 (YY1) suppresses esophageal squamous cell carcinoma development through heme oxygenase-1. Cancer Sci. 2013;104(11):1544-1551.
17. Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumor. 8th ed. Wiley; 2017.
18. Xu C, Chen Y, Zhang H, et al. Integrated microRNA-mRNA analyses reveal OPLL specific microRNA regulatory network using high-throughput sequencing. Sci Rep. 2016;6(5-6):21580.

ORCID iD
Pengfei Liu https://orcid.org/0000-0001-7122-9126
19. Ishibashi Y, Hanyu N, Suzuki Y, et al. Quantitative analysis of free ubiquitin and multi-ubiquitin chain in colorectal cancer. *Cancer Lett*. 2004;211(1):111-117.

20. Shirahashi H, Sakaida I, Terai S, Hironaka K, Kusano N, Okita K. Ubiquitin is a possible new predictive marker for the recurrence of human hepatocellular carcinoma. *Liver*. 2002;22(5):413-418.

21. Oh C, Park S, Lee EK, Yoo YJ. Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention. *Sci Rep*. 2013;3(9):2623.

22. Haakonsen DL, Rape M. Ubiquitin levels: the next target against gynecological cancers? *J Clin Invest*. 2017;127(12):4228-4230.

23. Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. *Biochim Biophys Acta*. 2013;1836(2):245-254.

24. Alkhateeb AA, Han B, Connor JR. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. *Breast Cancer Res Treat*. 2013;137(3):733-744.

25. Buranrat B, Connor JR. Cytoprotective effects of ferritin on doxorubicin-induced breast cancer cell death. *Oncol Rep*. 2015;34(5):2790-2796.

26. Song A, Eo W, Kim S, Shim B, Lee S. Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study. *BMC Complement Altern Med*. 2018;18(1):176.

27. Hu ZW, Wang L, Han Y, et al. Ferritin: a potential serum marker for lymph node metastasis in head and neck squamous cell carcinoma. *Oncol Lett*. 2019;17(1):314-322.

28. Wu T, Li Y, Liu B, et al. Expression of ferritin light chain (FTL) is elevated in glioblastoma, and FTL silencing inhibits glioblastoma cell proliferation via the GADD45/JNK pathway. *PLoS One*. 2016;11(2):e0149361.

29. Yu GH, Fu L, Chen J, Wei F, Shi WX. Decreased expression of ferritin light chain in osteosarcoma and its correlation with epithelial-mesenchymal transition. *Eur Rev Med Pharmacol Sci*. 2018;22(9):2580-2587.

30. Carpagnano GE, Lacedonia D, Palladino GP, et al. Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes? *Eur J Clin Invest*. 2012;42(5):478-486.

31. Karavias D, Maroulis I, Papadaki H, et al. Overexpression of CDT1 is a predictor of poor survival in patients with hepatocellular carcinoma. *J Gastrointest Surg*. 2016;20(3):568-579.

32. Mahadevappa R, Neves H, Yuen SM, et al. The prognostic significance of Cdc6 and Cdt1 in breast cancer. *Sci Rep*. 2017;7(1):985.

33. Eller MS, Muz P, Gilchrest BA. Regulation of CRABP II mRNA expression in human keratinocytes. *Exp Dermatol*. 1995;4(2):97-103.

34. Yang Q, Wang R, Xiao W, Sun F, Yuan H, Pan Q. Cellular retinoic acid binding protein 2 is strikingly downregulated in human esophageal squamous cell carcinoma and functions as a tumor suppressor. *PLoS One*. 2016;11(2):e0148381.

35. Oh C, Park S, Lee EK, Yoo YJ. Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention. *Sci Rep*. 2013;3:2623.